Viela Bio (NYSE:VIE) had its target price hoisted by equities researchers at Morgan Stanley from $35.00 to $54.00 in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 62.80% from the company’s current price.
Several other equities analysts have also recently issued reports on VIE. Zacks Investment Research cut Viela Bio from a “buy” rating to a “hold” rating in a report on Friday, February 21st. HC Wainwright began coverage on Viela Bio in a report on Tuesday, February 18th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Goldman Sachs Group cut Viela Bio from a “buy” rating to a “neutral” rating and set a $36.00 price target on the stock. in a report on Tuesday, February 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $47.40.
Shares of NYSE:VIE traded up $0.33 during midday trading on Thursday, reaching $33.17. The company’s stock had a trading volume of 17,533 shares, compared to its average volume of 93,644. Viela Bio has a fifty-two week low of $18.20 and a fifty-two week high of $70.66. The stock’s fifty day simple moving average is $41.20.
Viela Bio (NYSE:VIE) last announced its earnings results on Wednesday, March 25th. The company reported ($6.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($6.54).
A number of institutional investors and hedge funds have recently modified their holdings of VIE. Victory Capital Management Inc. bought a new position in Viela Bio during the fourth quarter worth about $99,000. New York State Common Retirement Fund bought a new position in shares of Viela Bio during the 4th quarter valued at about $133,000. American International Group Inc. bought a new position in shares of Viela Bio during the 4th quarter valued at about $93,000. State Street Corp bought a new position in shares of Viela Bio during the 4th quarter valued at about $1,559,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Viela Bio during the 4th quarter valued at about $1,221,000.
Viela Bio Company Profile
Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases.
Featured Story: What’s a Black Swan?
Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.